Interpace Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.7M | $46.9M | $40.0M | $5.7M | $8.2M | $32.4M | $24.2M | $21.9M |
| Cost of Revenue | $14.6M | $17.0M | $15.0M | $13.6M | $14.3M | $21.7M | $15.9M | $10.2M |
| Gross Profit | $24.1M | $29.9M | $25.1M | $18.2M | $18.8M | $10.7M | $8.3M | $11.7M |
| Gross Margin | 62.3% | 63.8% | 62.6% | 321.1% | 229.4% | 33.1% | 34.4% | 53.4% |
| Operating Expenses | ||||||||
| Research & Development | $642.0K | $676.0K | $636.0K | $703.0K | $1.5M | $2.8M | $2.8M | $2.1M |
| SG&A Expense | $9.5M | $9.5M | $9.4M | $11.0M | $10.7M | $18.2M | $14.4M | $8.7M |
| Operating Income | $4.1M | $8.1M | $4.0M | $-3.6M | $-6.3M | $-26.1M | $-26.4M | $-12.6M |
| Operating Margin | 10.5% | 17.3% | 9.9% | -63.7% | -77.3% | -80.5% | -109.1% | -57.7% |
| Interest Expense | — | — | — | — | — | $549.0K | $440.0K | $331.0K |
| Pretax Income | $3.8M | $7.0M | $2.3M | $-5.8M | $-7.7M | $-26.1M | $-26.7M | $-12.7M |
| Income Tax Expense | $-21.2M | $4.0K | $17.0K | $29.0K | $-705.0K | $53.0K | $-28.0K | $18.0K |
| Net Income | $24.6M | $6.7M | $2.0M | $-22.0M | $-14.9M | $-26.5M | $-26.7M | $-12.7M |
| Net Margin | 63.5% | 14.3% | 4.9% | -386.7% | -182.3% | -81.6% | -110.4% | -58.0% |
| EPS (Basic) | $5.55 | $1.42 | $0.11 | $-1.30 | $-0.90 | $-1.83 | $-1.81 | $-1.13 |
| EPS (Diluted) | $0.89 | $0.40 | $0.11 | $-1.30 | $-0.90 | $-1.83 | $-1.81 | $-1.13 |
| Shares Outstanding (Basic) | 4.4M | 4.4M | 17.3M | 17.0M | 16.5M | 16.1M | 15.0M | 11.3M |
| Shares Outstanding (Diluted) | 27.7M | 15.7M | 17.5M | 17.0M | 16.5M | 16.1M | 15.0M | 11.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |